AlphAIAlphAI — Financial news for AI agents
SEC EDGAR$BLTE

Chuang Hao-Yuan sold $66K of BLTE

Chuang Hao-Yuan (Chief Financial Officer) sold 367 shares of BELITE BIO, INC (BLTE) at an average of $180.35 ($180.00–$180.57) across 2 trades on 2026-08-12 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Chuang Hao-Yuan
Published Aug 14, 2026, 10:10 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 14, 2026, 10:16 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$BLTE
Neutral
medium confidence
Mentioned
$BLTE
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BLTENeutralLow
01

Why it matters

The newest disclosed fact is the CFO’s open-market sale of 367 shares on 2026-08-12, filed on 2026-08-14, under a pre-arranged 10b5-1 plan.

02

Market read

Traders may treat this as routine insider liquidity rather than a strong fundamental catalyst.

03

What to watch

The sale size is small relative to typical company float, and the price range ($180.00 to $180.57) suggests execution around a specific window rather than a broad directional bet.

Relevance 2/10Novelty 3/10Timing: filed 2026-08-14 after 2026-08-12 sale execution

Background

The article is a SEC Form 4 insider transaction disclosure for Belite Bio, Inc.

Company-level read

Ticker impact

$BLTENeutralMedium confidence
Context

Belite Bio CFO Chuang Hao-Yuan sold 367 shares in open-market transactions at about $180.35 per share under a 10b5-1 plan.

Expected impact

Low likelihood of a sustained price move solely from this Form 4 sale.

Evidence & confidence

The filing is an insider transaction (not a buy), but it is explicitly under a Rule 10b5-1 plan, which typically reduces interpretive value versus discretionary selling.

Market effects

Sector

No clear sector read-through from a single CFO 10b5-1 sale.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Even with 10b5-1, repeated insider selling can coincide with internal caution, so traders may still watch for follow-on disclosures.

Key entities

  • issuer
    BELITE BIO, INC

    Company whose CFO insider sale is disclosed on Form 4.

  • insider
    Chuang Hao-Yuan

    Chief Financial Officer and officer/director who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

BLTE insider trading history →

Related articles

$BLTEHighAI 8/10

Belite Bio Says Nasdaq Approved Move to Higher Listing Tier

Belite Bio (BLTE) announced its approval to move to Nasdaq's Global Select Market, starting Oct. 19. The company expects increased institutional investor attention and improved liquidity. Belite Bio is seeking approval for tinlarebant, its lead treatment for Stargardt disease, with the FDA setting a Feb. 12, 2027, action date.

econotimes.com
$BLTEMed

Belite Bio stock price target maintained at $245 by H.C. Wainwright

H.C. Wainwright maintained a $245 price target for Belite Bio (BLTE) after regulatory submissions in three countries. The stock is up 88% over the past year, with analysts showing strong optimism. Belite Bio submitted applications for tinlarebant, a treatment for Stargardt disease type 1, in Singapore, the UK, and Switzerland. The company aims for a global launch, with a first-mover advantage if approved.

investing.com
$BLTEMedAI 8/10

Belite Bio submits drug applications in Singapore, UK, Switzerland

Belite Bio (BLTE) submitted Marketing Authorization Applications for tinlarebant, a treatment for Stargardt disease type 1, in Singapore, the UK, and Switzerland. The company also filed applications in the US and Japan, with the US application receiving Priority Review. Tinlarebant met its primary endpoint in a Phase 3 trial and has received several regulatory designations.

investing.com